Spotlight on Pulmonary/Respiratory Medicine
Sarcoidosis: Considerations in the Management of Refractory Disease - Comprehensive Management of Sarcoidosis
StartActivity Details
Expires: February 10, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:- Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
- Utilize available assessments to appropriately identify refractory or progressive disease.
- Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.
Activity Description
Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.
Agenda
- Intro video
- Comprehensive Management of Sarcoidosis
- Faculty: Dr. Patel and Dr. Marts
Faculty
Activity Chair
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis
Research, Mallinkrodt
Faculty
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia
Disclosure:
Contracted Research: aTyr Pharma
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida
Disclosure: No relevant financial relationships to disclose.
Reviewer:
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.
How to Participate in this Activity and Obtain CME Credit
To participate in this activity, you must read the objectives, answer the
pretest question, view the content, and complete the posttest and evaluation.
Provide only one (1) correct answer for each question. A satisfactory score
is defined as answering the posttest question correctly. Upon receipt of the
completed materials, if a satisfactory score on the posttest is achieved,
Vindico Medical Education will issue an AMA PRA Category 1
Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: February 10, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:- Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
- Utilize available assessments to appropriately identify refractory or progressive disease.
- Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.
Activity Description
Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.
Agenda
- Intro video
- Comprehensive Management of Sarcoidosis
- Faculty: Dr. Patel and Dr. Marts
Faculty
Activity Chair
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis
Research, Mallinkrodt
Faculty
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia
Disclosure:
Contracted Research: aTyr Pharma
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida
Disclosure: No relevant financial relationships to disclose.
Reviewer:
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.
How to Participate in this Activity and Obtain CME Credit
To participate in this activity, you must read the objectives, answer the
pretest question, view the content, and complete the posttest and evaluation.
Provide only one (1) correct answer for each question. A satisfactory score
is defined as answering the posttest question correctly. Upon receipt of the
completed materials, if a satisfactory score on the posttest is achieved,
Vindico Medical Education will issue an AMA PRA Category 1
Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Pulmonary/Respiratory Medicine Presentations
Small Cell Lung Cancer: Optimism Through Immunotherapeutic Approaches
StartActivity Details
/ MOC point(s)
Expires: May 14, 2021
Accredited By
Target Audience
This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with SCLC.
Learning Objectives
- Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
- Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
- Incorporate immunotherapy into the management of patients with SCLC where appropriate
- Identify and manage immune-related adverse events associated with checkpoint inhibitors
Activity Description
In this interactive panel discussion, oncology experts and a patient with SCLC discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.
Statement of Educational Need
Small cell lung cancer is an aggressive form of lung cancer that is historically associated with limited treatment options and low survival rates. However, in the last few years immunotherapies have emerged as effective treatment options for SCLC, particularly in people with extensive-stage disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the efficacy, safety, and tolerability of immunotherapies, the rationale for use in SCLC, and how to incorporate these treatments into SCLC management.
Agenda
This activity will address the following topics:
- Role of the immune system in tumor pathogenesis
- Rationale for immunotherapy in SCLC
- Brief overview of the mechanism of action of immunotherapy
- Evidence on the safety and efficacy of approved and emerging immune checkpoint inhibitors
- Recognizing and managing immune-mediated adverse reactions associated with immunotherapy
- Description of ongoing and planned clinical trials of immunotherapy for SCLC
- Identifying patients who may benefit from immunotherapy
Faculty
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA
Hossein Borghaei, DO, MS, is the chief of Thoracic Oncology and a professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center in Philadelphia, PA. He earned his medical degree at Philadelphia College of Osteopathic Medicine and completed his residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer. Dr. Borghaei is board certified in medical oncology.
Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a Phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.
Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, and NCCN and ECOG thoracic committees. Dr. Borghaei has published in many peer-reviewed publications, including The New England Journal of Medicine, The Lancet Oncology, Lung Cancer, and the Journal of Thoracic Oncology.
Hossein Borghaei, DO, MS, has affiliations with AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol-Myers Squibb, Cantargia AB, Celgene, Daiichi, EMD-Serono, Genentech, Genmab, GLG, Huya Bio, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda (Consultant); Merck/Celgene, Millennium, Bristol-Myers Squibb/Lilly (To Institution) (Contracted Research); Incyte, Takeda, U of Pennsylvania (Data Safety Monitoring Board); Rgenix, Sonnetbio (Stock).
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director of Thoracic Oncology
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA
Taofeek K. Owonikoko, MD, PhD, MSCR, is Professor and Vice-Chair for Faculty Development in the Department of Hematology and Medical Oncology and Co-Leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University. Dr. Owonikoko received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria. He completed his residency in anatomic pathology at the Lagos University Teaching Hospital and later proceeded to Dusseldorf, Germany for further training in anatomic pathology at the Heinrich Heine University. He received his PhD degree in anatomic pathology from the Heinrich Heine University, after which he proceeded to the Johns Hopkins University in Baltimore for postdoctoral training in molecular imaging. Dr. Owonikoko is board certified in medical oncology.
Dr. Owonikoko is a world-renowned expert in the treatment of lung cancer. He is particularly interested in advancing the care of and improving the outcomes for small cell lung cancer (SCLC). He leads an active clinical and research program at the Winship Cancer Institute at Emory University looking at new treatment strategies for patients through clinical trials and translational research work in the lab. Dr. Owonikoko has received awards on his leadership, including the IASLC Heine H. Hansen Lectureship Award and the NCI Cancer Clinical Investigator Team Leadership Award. He has also been published in many peer-reviewed journals, including the Journal of Thoracic Oncology, The Cancer Journal, Clinical Cancer Research, and Molecular Oncology.
Taofeek Owonikoko, MD, PhD, MSCR, has affiliations with AbbVie, Amgen, ARMO BioScience, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Merck, Novartis, Sandoz, Seattle Genetics, PharmaMar, Takeda, XCovery (Consulting/Advisory Board); AbbVie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZenea/MedImmune, Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, StemCentRx, United Therapeutics, EMD Serono, Roche/Genentech (IRC/DSMB); Cambium Oncology (Stock).
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA
Kristen Kreamer, CRNP, AOCNP, APRN, BC, is a medical oncology nurse practitioner at Fox Chase Cancer Center in Philadelphia, PA. Ms. Kreamer earned her MS in nursing from Yale University in New Haven, CT, and worked as a clinical nurse specialist for 12 years before completing a post-masters certification as an oncology nurse practitioner at the University of Pennsylvania in Philadelphia, PA.
Ms. Kreamer’s practice includes patients with lung and head and neck malignancies and she also works with the Lung Cancer Screening and Tobacco Treatment programs at Fox Chase. She is a member of the Oncology Nursing Society, the Advanced Practice Society for Hematology/Oncology and Sigma Theta Tau International. Ms. Kreamer has been published in The Journal for Advanced Practitioners in Oncology and other peer-reviewed publications.
Kristen Kreamer, CRNP, AOCNP, APRN, BC, has affiliations with AstraZeneca (Speakers Bureau).
Cedric White (Patient)
Cedric White has nothing to disclose.
Conflict of Interest Policy/Disclosure Statement
AKH planners and reviewers have no financial
relationships to disclose.
RMEI Medical Education, LLC planners and managers have no
financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner, has no
financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has
no financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside of
the labeled indications. The opinions expressed in this educational activity
are those of the faculty and do not necessarily represent the views of the
planners. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to serve
as a guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed or suggested in this activity
should not be used by clinicians without evaluation of their patient’s
conditions and possible contraindications and/or dangers in use, review of
any applicable manufacturer’s product information, and comparison with
recommendations of other authorities.
Disclosure Declaration
It is the policy of AKH Inc.
and RMEI Medical Education, LLC to ensure independence, balance, objectivity,
scientific rigor, and integrity in all of its continuing education
activities. The faculty must disclose to the participants any significant
relationships with commercial interests whose products or devices may be
mentioned in the activity or with the commercial supporter of this continuing
education activity. Identified conflicts of interest are resolved by AKH
prior to accreditation of the activity and may include any of or combination
of the following: attestation to non-commercial content; notification of
independent and certified CME expectations; referral to National Faculty
Initiative training; restriction of topic area or content; restriction to
discussion of science only; amendment of content to eliminate discussion of
device or technique; use of other faculty for discussion of recommendations;
independent review against criteria ensuring evidence support recommendation;
moderator review; and peer review.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA)
accepts AMA PRA Category 1 Credit(s)™ from
organizations accredited by ACCME.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 MOC points 0 patient safety in the
American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. Participants will earn MOC points equivalent to the amount of
CME credits claimed for the activity. It is the CME activity provider's
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must complete the following steps:
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI),
a full-service medical education company. The winner will be selected via
automated random drawing on a monthly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This educational activity is supported by independent medical educational grants from AstraZeneca and Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Activity Details
/ MOC point(s)
Expires: May 14, 2021
Accredited By
Target Audience
This activity is intended for oncologists, pulmonologists, pathologists, advanced practice nurses, nurse practitioners, and PAs who manage patients with SCLC.
Learning Objectives
- Describe the role of the immune system in tumor pathogenesis and how immunotherapy can be utilized to modulate the anti-tumor immune response
- Evaluate current and emerging immunotherapies for the management of small cell lung cancer (SCLC) on the basis of clinical trial safety and efficacy data
- Incorporate immunotherapy into the management of patients with SCLC where appropriate
- Identify and manage immune-related adverse events associated with checkpoint inhibitors
Activity Description
In this interactive panel discussion, oncology experts and a patient with SCLC discuss recent advances in the use of immunotherapy for SCLC management. Experts present the latest efficacy data supporting the use of immune checkpoint inhibitors and strategies for managing treatment-related adverse events. An experienced patient with SCLC provides his unique perspective on treatment administration, education, and expectations. The panel concludes by addressing the personalized selection of patients with SCLC who may benefit from immunotherapy.
Statement of Educational Need
Small cell lung cancer is an aggressive form of lung cancer that is historically associated with limited treatment options and low survival rates. However, in the last few years immunotherapies have emerged as effective treatment options for SCLC, particularly in people with extensive-stage disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the efficacy, safety, and tolerability of immunotherapies, the rationale for use in SCLC, and how to incorporate these treatments into SCLC management.
Agenda
This activity will address the following topics:
- Role of the immune system in tumor pathogenesis
- Rationale for immunotherapy in SCLC
- Brief overview of the mechanism of action of immunotherapy
- Evidence on the safety and efficacy of approved and emerging immune checkpoint inhibitors
- Recognizing and managing immune-mediated adverse reactions associated with immunotherapy
- Description of ongoing and planned clinical trials of immunotherapy for SCLC
- Identifying patients who may benefit from immunotherapy
Faculty
Chief, Thoracic Oncology
Professor, Department of Hematology and Oncology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
Philadelphia, PA
Hossein Borghaei, DO, MS, is the chief of Thoracic Oncology and a professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center in Philadelphia, PA. He earned his medical degree at Philadelphia College of Osteopathic Medicine and completed his residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer. Dr. Borghaei is board certified in medical oncology.
Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a Phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.
Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, and NCCN and ECOG thoracic committees. Dr. Borghaei has published in many peer-reviewed publications, including The New England Journal of Medicine, The Lancet Oncology, Lung Cancer, and the Journal of Thoracic Oncology.
Hossein Borghaei, DO, MS, has affiliations with AbbVie, Amgen, AstraZeneca, Axiom, Boehringer Ingelheim, BioNTech, Bristol-Myers Squibb, Cantargia AB, Celgene, Daiichi, EMD-Serono, Genentech, Genmab, GLG, Huya Bio, Lilly, Merck, Novartis, Pfizer, PharmaMar, Regeneron, Takeda (Consultant); Merck/Celgene, Millennium, Bristol-Myers Squibb/Lilly (To Institution) (Contracted Research); Incyte, Takeda, U of Pennsylvania (Data Safety Monitoring Board); Rgenix, Sonnetbio (Stock).
Professor and Vice-Chair, Faculty Development
Department of Hematology and Medical Oncology
Chair, Thoracic Malignancies Working Group
Director of Thoracic Oncology
Co-Leader, Discovery & Developmental Therapeutics Program
Winship Cancer Institute
Emory University
Druid Hills, GA
Taofeek K. Owonikoko, MD, PhD, MSCR, is Professor and Vice-Chair for Faculty Development in the Department of Hematology and Medical Oncology and Co-Leader of the Discovery & Developmental Therapeutics Program at the Winship Cancer Institute of Emory University. Dr. Owonikoko received his primary medical training at the Obafemi Awolowo University in Ile-Ife, Nigeria. He completed his residency in anatomic pathology at the Lagos University Teaching Hospital and later proceeded to Dusseldorf, Germany for further training in anatomic pathology at the Heinrich Heine University. He received his PhD degree in anatomic pathology from the Heinrich Heine University, after which he proceeded to the Johns Hopkins University in Baltimore for postdoctoral training in molecular imaging. Dr. Owonikoko is board certified in medical oncology.
Dr. Owonikoko is a world-renowned expert in the treatment of lung cancer. He is particularly interested in advancing the care of and improving the outcomes for small cell lung cancer (SCLC). He leads an active clinical and research program at the Winship Cancer Institute at Emory University looking at new treatment strategies for patients through clinical trials and translational research work in the lab. Dr. Owonikoko has received awards on his leadership, including the IASLC Heine H. Hansen Lectureship Award and the NCI Cancer Clinical Investigator Team Leadership Award. He has also been published in many peer-reviewed journals, including the Journal of Thoracic Oncology, The Cancer Journal, Clinical Cancer Research, and Molecular Oncology.
Taofeek Owonikoko, MD, PhD, MSCR, has affiliations with AbbVie, Amgen, ARMO BioScience, AstraZeneca, Bayer, BerGenBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, EMD Serono, G1 Therapeutics, Heron Pharmaceutical, Lilly, MedImmune, Merck, Novartis, Sandoz, Seattle Genetics, PharmaMar, Takeda, XCovery (Consulting/Advisory Board); AbbVie, Aeglea Biotherapeutics, Amgen, Astellas Pharma, AstraZenea/MedImmune, Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Fujifilm, G1 Therapeutics, Incyte, Loxo/Lilly, Merck, Novartis, Pfizer, Regeneron, StemCentRx, United Therapeutics, EMD Serono, Roche/Genentech (IRC/DSMB); Cambium Oncology (Stock).
Nurse Practitioner, Thoracic and Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA
Kristen Kreamer, CRNP, AOCNP, APRN, BC, is a medical oncology nurse practitioner at Fox Chase Cancer Center in Philadelphia, PA. Ms. Kreamer earned her MS in nursing from Yale University in New Haven, CT, and worked as a clinical nurse specialist for 12 years before completing a post-masters certification as an oncology nurse practitioner at the University of Pennsylvania in Philadelphia, PA.
Ms. Kreamer’s practice includes patients with lung and head and neck malignancies and she also works with the Lung Cancer Screening and Tobacco Treatment programs at Fox Chase. She is a member of the Oncology Nursing Society, the Advanced Practice Society for Hematology/Oncology and Sigma Theta Tau International. Ms. Kreamer has been published in The Journal for Advanced Practitioners in Oncology and other peer-reviewed publications.
Kristen Kreamer, CRNP, AOCNP, APRN, BC, has affiliations with AstraZeneca (Speakers Bureau).
Cedric White (Patient)
Cedric White has nothing to disclose.
Conflict of Interest Policy/Disclosure Statement
AKH planners and reviewers have no financial
relationships to disclose.
RMEI Medical Education, LLC planners and managers have no
financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner, has no
financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has
no financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside of
the labeled indications. The opinions expressed in this educational activity
are those of the faculty and do not necessarily represent the views of the
planners. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to serve
as a guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed or suggested in this activity
should not be used by clinicians without evaluation of their patient’s
conditions and possible contraindications and/or dangers in use, review of
any applicable manufacturer’s product information, and comparison with
recommendations of other authorities.
Disclosure Declaration
It is the policy of AKH Inc.
and RMEI Medical Education, LLC to ensure independence, balance, objectivity,
scientific rigor, and integrity in all of its continuing education
activities. The faculty must disclose to the participants any significant
relationships with commercial interests whose products or devices may be
mentioned in the activity or with the commercial supporter of this continuing
education activity. Identified conflicts of interest are resolved by AKH
prior to accreditation of the activity and may include any of or combination
of the following: attestation to non-commercial content; notification of
independent and certified CME expectations; referral to National Faculty
Initiative training; restriction of topic area or content; restriction to
discussion of science only; amendment of content to eliminate discussion of
device or technique; use of other faculty for discussion of recommendations;
independent review against criteria ensuring evidence support recommendation;
moderator review; and peer review.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA)
accepts AMA PRA Category 1 Credit(s)™ from
organizations accredited by ACCME.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 MOC points 0 patient safety in the
American Board of Internal Medicine's (ABIM) Maintenance of Certification
(MOC) program. Participants will earn MOC points equivalent to the amount of
CME credits claimed for the activity. It is the CME activity provider's
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must complete the following steps:
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI),
a full-service medical education company. The winner will be selected via
automated random drawing on a monthly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This educational activity is supported by independent medical educational grants from AstraZeneca and Merck Sharp & Dohme Corp.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Managing Idiopathic Pulmonary Fibrosis: Recent Clinical Advances and Long-Term Outcomes - Accelerating and Improving Accuracy in Diagnosis of Patients with IPF
StartActivity Details
Expires: April 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, radiologists, and other health care professionals involved in the management of patients with idiopathic pulmonary fibrosis (IPF).
Learning Objective
Upon successful completion of this activity, participants should be better able to utilize the most recent guidelines for the diagnosis of patients with IPF to ensure early and appropriate intervention.
Activity Description
IPF is a chronic progressive lung disease of unknown origin. To avoid misdiagnosis and delayed or inappropriate management of IPF, it is imperative to distinguish IPF from other types of interstitial lung disease. In 2018, updated guidelines with additional criteria for the diagnosis of IPF were published by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. In this video presentation, Dr. Fernando J. Martinez discusses how these updated guidelines can ensure early and appropriate intervention.
Faculty
Chief
Division of Pulmonary and Critical Care Medicine
Weill Cornell Medicine
New York, NY
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Bridge Biotherapeutics, Chiesi, Gala, Genentech, GlaxoSmithKline, ProterixBio, Sunovion
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Afferent/Merck, AstraZeneca, Biogen, Boehringer Ingelheim, GlaxoSmithKline, Nitto Avecia Pharma Services, Promedior, Prometic, Patara/Respivant, Veracyte
Data Safety & Monitoring Board: Biogen, Boehringer Ingelheim, Genentech, GlaxoSmithKline
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
- Disclosure: No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 30, 2020 to April 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer
the pretest question, view the CME content, and complete the posttest and
evaluation. Provide only one (1) correct answer for each question. A
satisfactory score is defined as answering the posttest question correctly.
Upon receipt of the completed materials, if a satisfactory score on the
posttest is achieved, Vindico Medical Education will issue an AMA PRA
Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: April 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, radiologists, and other health care professionals involved in the management of patients with idiopathic pulmonary fibrosis (IPF).
Learning Objective
Upon successful completion of this activity, participants should be better able to utilize the most recent guidelines for the diagnosis of patients with IPF to ensure early and appropriate intervention.
Activity Description
IPF is a chronic progressive lung disease of unknown origin. To avoid misdiagnosis and delayed or inappropriate management of IPF, it is imperative to distinguish IPF from other types of interstitial lung disease. In 2018, updated guidelines with additional criteria for the diagnosis of IPF were published by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. In this video presentation, Dr. Fernando J. Martinez discusses how these updated guidelines can ensure early and appropriate intervention.
Faculty
Chief
Division of Pulmonary and Critical Care Medicine
Weill Cornell Medicine
New York, NY
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Bridge Biotherapeutics, Chiesi, Gala, Genentech, GlaxoSmithKline, ProterixBio, Sunovion
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Afferent/Merck, AstraZeneca, Biogen, Boehringer Ingelheim, GlaxoSmithKline, Nitto Avecia Pharma Services, Promedior, Prometic, Patara/Respivant, Veracyte
Data Safety & Monitoring Board: Biogen, Boehringer Ingelheim, Genentech, GlaxoSmithKline
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
- Disclosure: No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 30, 2020 to April 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer
the pretest question, view the CME content, and complete the posttest and
evaluation. Provide only one (1) correct answer for each question. A
satisfactory score is defined as answering the posttest question correctly.
Upon receipt of the completed materials, if a satisfactory score on the
posttest is achieved, Vindico Medical Education will issue an AMA PRA
Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Managing Idiopathic Pulmonary Fibrosis: Recent Clinical Advances and Long-Term Outcomes - Available Agents in IPF: Outcomes Five Years Later
StartActivity Details
Expires: April 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, radiologists, and other health care professionals involved in the management of patients with idiopathic pulmonary fibrosis (IPF).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate the latest long-term evidence regarding approved therapies for IPF, including impact on hospitalization rates, need for transplant, and life expectancy.
- Incorporate the most recent clinical advances into therapeutic approaches for patients with IPF.
Activity Description
IPF is a chronic progressive lung disease of unknown origin. Early and accurate diagnosis of patients with IPF is imperative to ensure appropriate therapeutic intervention. The approval of 2 antifibrotic therapies for the treatment of IPF patients has dramatically enhanced the therapeutic landscape for these patients, providing the potential for improved long-term outcomes. In this video presentation, Dr. Robert J. Kaner reviews the latest long-term evidence regarding approved IPF therapies, discusses the impact of these therapies on patient outcomes, and provides insight into the emerging therapeutic pipeline.
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Consulting Fee: Boehringer Ingelheim, Roche/Genentech
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Contracted Research: Boehringer Ingelheim, Roche/Genentech
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
- Disclosure: No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 30, 2020 to April 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer
the pretest question, view the CME content, and complete the posttest and
evaluation. Provide only one (1) correct answer for each question. A
satisfactory score is defined as answering the posttest question correctly.
Upon receipt of the completed materials, if a satisfactory score on the
posttest is achieved, Vindico Medical Education will issue an AMA PRA
Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: April 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, radiologists, and other health care professionals involved in the management of patients with idiopathic pulmonary fibrosis (IPF).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate the latest long-term evidence regarding approved therapies for IPF, including impact on hospitalization rates, need for transplant, and life expectancy.
- Incorporate the most recent clinical advances into therapeutic approaches for patients with IPF.
Activity Description
IPF is a chronic progressive lung disease of unknown origin. Early and accurate diagnosis of patients with IPF is imperative to ensure appropriate therapeutic intervention. The approval of 2 antifibrotic therapies for the treatment of IPF patients has dramatically enhanced the therapeutic landscape for these patients, providing the potential for improved long-term outcomes. In this video presentation, Dr. Robert J. Kaner reviews the latest long-term evidence regarding approved IPF therapies, discusses the impact of these therapies on patient outcomes, and provides insight into the emerging therapeutic pipeline.
Faculty
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY
Consulting Fee: Boehringer Ingelheim, Roche/Genentech
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech
Contracted Research: Boehringer Ingelheim, Roche/Genentech
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
- Disclosure: No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 30, 2020 to April 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer
the pretest question, view the CME content, and complete the posttest and
evaluation. Provide only one (1) correct answer for each question. A
satisfactory score is defined as answering the posttest question correctly.
Upon receipt of the completed materials, if a satisfactory score on the
posttest is achieved, Vindico Medical Education will issue an AMA PRA
Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Managing Idiopathic Pulmonary Fibrosis: Recent Clinical Advances and Long-Term Outcomes - Communicating with Patients to Improve Adherence to Therapy
StartActivity Details
Expires: April 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, radiologists, and other health care professionals involved in the management of patients with idiopathic pulmonary fibrosis (IPF).
Learning Objective
Upon successful completion of this activity, participants should be better able to implement strategies to improve communication with patients with IPF regarding the importance of continuing treatment to optimize long-term outcomes.
Activity Description
IPF is a chronic progressive lung disease of unknown origin. Although 2 recently approved antifibrotic therapies have shown enhanced patient outcomes, people with IPF continue to have unmet needs. Health care providers have the potential to improve patients’ adherence to therapy and quality of life by engaging these patients and their caregivers in shared decision-making, providing education on disease management, and offering access to patient advocacy groups. In this video presentation, Dr. Maria L. Padilla discusses the unmet needs of patients with IPF, strategies to improve communication with these patients and their caregivers, and how ongoing treatment is critical to optimizing long-term outcomes.
Faculty
Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine
Director, Pulmonary Fibrosis/ILD Program
Mount Sinai Medical Center
New York, NY
Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Celgene
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
- Disclosure: No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 30, 2020 to April 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer
the pretest question, view the CME content, and complete the posttest and
evaluation. Provide only one (1) correct answer for each question. A
satisfactory score is defined as answering the posttest question correctly.
Upon receipt of the completed materials, if a satisfactory score on the
posttest is achieved, Vindico Medical Education will issue an AMA PRA
Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: April 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, radiologists, and other health care professionals involved in the management of patients with idiopathic pulmonary fibrosis (IPF).
Learning Objective
Upon successful completion of this activity, participants should be better able to implement strategies to improve communication with patients with IPF regarding the importance of continuing treatment to optimize long-term outcomes.
Activity Description
IPF is a chronic progressive lung disease of unknown origin. Although 2 recently approved antifibrotic therapies have shown enhanced patient outcomes, people with IPF continue to have unmet needs. Health care providers have the potential to improve patients’ adherence to therapy and quality of life by engaging these patients and their caregivers in shared decision-making, providing education on disease management, and offering access to patient advocacy groups. In this video presentation, Dr. Maria L. Padilla discusses the unmet needs of patients with IPF, strategies to improve communication with these patients and their caregivers, and how ongoing treatment is critical to optimizing long-term outcomes.
Faculty
Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine
Director, Pulmonary Fibrosis/ILD Program
Mount Sinai Medical Center
New York, NY
Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Celgene
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
- Disclosure: No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 30, 2020 to April 29, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer
the pretest question, view the CME content, and complete the posttest and
evaluation. Provide only one (1) correct answer for each question. A
satisfactory score is defined as answering the posttest question correctly.
Upon receipt of the completed materials, if a satisfactory score on the
posttest is achieved, Vindico Medical Education will issue an AMA PRA
Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Eosinophilic Granulomatosis with Polyangiitis Curbside Consults: Case 1 - Differentiating EGPA from Other Eosinophilic Disorders
StartActivity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to review the latest understanding regarding the immunopathology and clinical features of EGPA to better differentiate from related vasculitides or eosinophilic conditions.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Curry Koening, MD, MS, discuss the immunopathology and clinical features of eosinophilic granulomatosis with polyangiitis (EGPA), providing guidance on differentiating EGPA from related vasculitides or eosinophilic conditions.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to review the latest understanding regarding the immunopathology and clinical features of EGPA to better differentiate from related vasculitides or eosinophilic conditions.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Curry Koening, MD, MS, discuss the immunopathology and clinical features of eosinophilic granulomatosis with polyangiitis (EGPA), providing guidance on differentiating EGPA from related vasculitides or eosinophilic conditions.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Eosinophilic Granulomatosis with Polyangiitis Curbside Consults: Case 2 – Establishing an EGPA Diagnosis
StartActivity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to review the latest understanding regarding the immunopathology and clinical features of EGPA to better differentiate from related vasculitides or eosinophilic conditions.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Sebastian Unizony, MD, discuss pearls for establishing a diagnosis of EGPA.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to review the latest understanding regarding the immunopathology and clinical features of EGPA to better differentiate from related vasculitides or eosinophilic conditions.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Sebastian Unizony, MD, discuss pearls for establishing a diagnosis of EGPA.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Eosinophilic Granulomatosis with Polyangiitis Curbside Consults: Case 3 - Initiating Therapy for EGPA
StartActivity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the latest understanding regarding the immunopathology and clinical features of EGPA to better differentiate from related vasculitides or eosinophilic conditions.
- Assess the burden of various disease symptoms on quality of life for patients with EGPA.
- Apply the latest clinical advances to the treatment of patients with EGPA.
- Identify patients with EGPA who may benefit from glucocorticoid-sparing options.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Adam Brown, MD, discuss principles of initiating therapy for a newly diagnosed patient with eosinophilic granulomatosis with polyangiitis (EGPA).
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the latest understanding regarding the immunopathology and clinical features of EGPA to better differentiate from related vasculitides or eosinophilic conditions.
- Assess the burden of various disease symptoms on quality of life for patients with EGPA.
- Apply the latest clinical advances to the treatment of patients with EGPA.
- Identify patients with EGPA who may benefit from glucocorticoid-sparing options.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Adam Brown, MD, discuss principles of initiating therapy for a newly diagnosed patient with eosinophilic granulomatosis with polyangiitis (EGPA).
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Eosinophilic Granulomatosis with Polyangiitis Curbside Consults: Case 4 - Steroid-Sparing Approaches to EGPA Therapy
StartActivity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the burden of various disease symptoms on quality of life for patients with EGPA.
- Apply the latest clinical advances to the treatment of patients with EGPA.
- Identify patients with EGPA who may benefit from glucocorticoid-sparing options.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Curry Koening, MD, MS, explore steroid-sparing options for a patient with eosinophilic granulomatosis with polyangiitis (EGPA) who is experiencing adverse effects from long-term glucocorticoid therapy to control her asthma symptoms.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the burden of various disease symptoms on quality of life for patients with EGPA.
- Apply the latest clinical advances to the treatment of patients with EGPA.
- Identify patients with EGPA who may benefit from glucocorticoid-sparing options.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Curry Koening, MD, MS, explore steroid-sparing options for a patient with eosinophilic granulomatosis with polyangiitis (EGPA) who is experiencing adverse effects from long-term glucocorticoid therapy to control her asthma symptoms.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Eosinophilic Granulomatosis with Polyangiitis Curbside Consults: Case 5 - Managing EGPA With Recalcitrant Asthma
StartActivity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the burden of various disease symptoms on quality of life for patients with EGPA.
- Apply the latest clinical advances to the treatment of patients with EGPA.
- Identify patients with EGPA who may benefit from glucocorticoid-sparing options.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Sebastian Unizony, MD, discuss recent advances in EGPA treatment options for a patient with EGPA and recalcitrant asthma. Faculty discuss the evidence for mepolizumab, an interleukin-5 inhibitor that was recently approved for treating adults with EGPA.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 30, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, allergists, pulmonologists, and other health care professionals involved in the management of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the burden of various disease symptoms on quality of life for patients with EGPA.
- Apply the latest clinical advances to the treatment of patients with EGPA.
- Identify patients with EGPA who may benefit from glucocorticoid-sparing options.
Activity Description
In this case-based video, Leonard Calabrese, DO, and Sebastian Unizony, MD, discuss recent advances in EGPA treatment options for a patient with EGPA and recalcitrant asthma. Faculty discuss the evidence for mepolizumab, an interleukin-5 inhibitor that was recently approved for treating adults with EGPA.
Series Description
In these Curbside Consults, expert faculty discuss clinical cases to provide insight into the workup, diagnosis, and treatment of patients with EGPA. Faculty explore the latest understanding regarding the immunopathology and clinical features of EGPA and provide pearls for establishing an EGPA diagnosis and initiating therapy. Additionally, our experts review glucocorticoid-sparing therapy options for treating EGPA.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Faculty
Center for Vasculitis Care and Research
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Disclosure:
Honorarium: Healio
Associate Professor of Medicine
Director, Vasculitis Clinic
University of Utah Health Sciences Center and Salt Lake City Veterans Affairs Medical Center
Salt Lake City, UT
Disclosure:
Consulting Fee: ChemoCentryx, Genentech, Roche
Co-Director, Vasculitis and Glomerulonephritis Center
Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosure:
Consulting Fee: Kiniksa, Sanofi
Contracted Research (paid to institution): Genentech, Janssen
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Sarcoidosis: Considerations in the Management of Refractory Disease - Neurosarcoidosis
StartActivity Details
Expires: February 10, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:- Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
- Utilize available assessments to appropriately identify refractory or progressive disease.
- Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
- Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.
Activity Description
Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.
Agenda
- Neurosarcoidosis
- Faculty: Dr. Culver and Dr. Patel
Faculty
Activity Chair
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis
Research, Mallinkrodt
Faculty
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia
Disclosure:
Contracted Research: aTyr Pharma
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida
Disclosure: No relevant financial relationships to disclose.
Reviewer:
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.
How to Participate in this Activity and Obtain CME Credit
To participate in this activity, you must read the objectives, answer the
pretest question, view the content, and complete the posttest and evaluation.
Provide only one (1) correct answer for each question. A satisfactory score
is defined as answering the posttest question correctly. Upon receipt of the
completed materials, if a satisfactory score on the posttest is achieved,
Vindico Medical Education will issue an AMA PRA Category 1
Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: February 10, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is pulmonologists, neurologists, cardiologists, and other health care professionals involved in the management of patients with sarcoidosis.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:- Identify the clinical signs and symptoms of pulmonary and extrapulmonary manifestations of sarcoidosis.
- Utilize available assessments to appropriately identify refractory or progressive disease.
- Incorporate knowledge of available clinical evidence to select among treatment options for refractory sarcoidosis.
- Implement strategies to optimize patient-centered care and coordination within a multidisciplinary care team.
Activity Description
Sarcoidosis is a multisystem inflammatory disease that can affect 1 or more organs. It is newly diagnosed in an estimated 25,000 persons each year, with approximately 185,000 patients seeking medical care per year. Sarcoidosis most often affects the lung, but it is highly variable and almost any organ can be affected. Cutaneous, ocular, renal, cardiac, neurologic, gastrointestinal, and musculoskeletal manifestations are possible. Although many patients respond to first-line therapy or experience spontaneous resolution of the condition, a subset of patients are refractory to initial therapy, experiencing significant morbidity and mortality associated with disease progression as well as sarcoidosis-associated complications. In this educational activity, expert clinicians will discuss optimal ways to diagnose and manage patients with sarcoidosis.
Agenda
- Neurosarcoidosis
- Faculty: Dr. Culver and Dr. Patel
Faculty
Activity Chair
Director, Interstitial Lung Disease Program
Cleveland Clinic
Cleveland, OH
Disclosure:
Consulting Fee: aTyr Pharma
Contracted Research: aTyr Pharma, Foundation for Sarcoidosis
Research, Mallinkrodt
Faculty
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia
Disclosure:
Contracted Research: aTyr Pharma
Clinical Assistant Professor
Division of Pulmonary, Critical Care & Sleep Medicine
University of Florida Health
Gainesville, Florida
Disclosure: No relevant financial relationships to disclose.
Reviewer:
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, February 11, 2020 to February 10, 2021.
How to Participate in this Activity and Obtain CME Credit
To participate in this activity, you must read the objectives, answer the
pretest question, view the content, and complete the posttest and evaluation.
Provide only one (1) correct answer for each question. A satisfactory score
is defined as answering the posttest question correctly. Upon receipt of the
completed materials, if a satisfactory score on the posttest is achieved,
Vindico Medical Education will issue an AMA PRA Category 1
Credit(s)™ Certificate.
MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the
Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program
(QPP). Participants who successfully complete the activity and its
performance assessment will receive printable documentation of successful
completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP,
accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com